Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody aims to reverse cancer wasting

NCT ID NCT06868849

Recruiting now Symptom relief Sponsor: Shanghai JMT-Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called JMT203 in people with lung, pancreatic, or colorectal cancer who are experiencing cachexia (severe weight loss and muscle wasting). The drug is an antibody that targets a protein linked to appetite loss. The trial will enroll about 307 participants and will first check safety and dosing, then measure if it helps patients gain weight over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JMT203 (a monoclonal antibody that blocks GFRAL, a protein involved in appetite and weight loss)
What this could lead to
If it works, this could lead to a treatment that helps cancer patients maintain or gain weight and improve their quality of life.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe. Side effects from the antibody are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm non-small cell lung carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CACHEXIA COLORECTAL CANCER CACHEXIA NON-SMALL CELL LUNG CANCER PANCREATIC CANCER PANCREATIC CANCER CACHEXIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sir run run shaw Hospital

    RECRUITING

    Zhejiang, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.